Effects of route of administration on neural exposure to platinum-based chemotherapy treatment: a pharmacokinetic study in rat

The persisting need for effective clinical treatment of chemotherapy-induced neurotoxicity (CIN) motivates critical evaluation of preclinical models of CIN for their translational relevance. The present study aimed to provide the first quantitative evaluation of neural tissue exposed in vivo to a platinum-based anticancer compound, oxaliplatin (OX) during and after two commonly used dosing regimens: slow IV infusion used clinically and bolus IP injection used preclinically. Inductively-coupled plasma mass spectrometry analysis of dorsal root ganglia indicated that while differences in the temporal dynamics of platinum distribution exist, key drivers of neurotoxicity, e.g. peak concentrations and exposure, were not different across the two routes of administration. We conclude that the IP route of OX administration achieves clinically relevant pharmacokinetic exposure of neural tissues in a rodent model of CIN.

Automated summary

The study quantitatively evaluated neural tissue exposed to oxaliplatin (OX) in vivo, finding that the intraperitoneal (IP) route of administration achieves clinically relevant pharmacokinetic exposure in a rodent model of CIN.